| STATUS |
Co has completed a Phase I clinical study to assess safety, tolerability and pharmacokinetics following a single oral administration. Results of the study suggest that our compound was well tolerated at all doses. The study also demonstrated that presence of the drug was detectable in the bloodstream at all doses administered and remains in circulation long enough to allow once or twice daily dosing. Co maintains the unencumbered, worldwide rights to the IgE down regulation platform. We are currently seeking out-licensing opportunities on a worldwide basis, for collaborative research, development and commercialization initiatives |
| COMPANY | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |